Caffeine, postmenopausal estrogen, and risk of Parkinson's disease

Neurology

Volumn 60, Issue 5, 2003, Pages 790-795

  Ascherio, Alberto ^a,c   Chen, H ^a   Schwarzschild, M A ^b   Zhang, S M ^a,c   Colditz, G A ^a,c   Speizer, F E ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; ESTROGEN; HORMONE;

ADULT; ARTICLE; COFFEE; DISEASE ASSOCIATION; FEMALE; FOOD INTAKE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 0037432281     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000046523.05125.87     Document Type: Article

References (55)

1. Ross GW, Abbott RD, Petrovich H, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 2000;283: 2674-2679.
2. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
3. Hellenbrand W, Seidler A, Robra B-P, et al. Smoking and Parkinson's disease: a case control study in Germany. Int J Epidemiol 1997;26:328-339.
4. Fall P, Frederikson M, Axelson O, Granérus A. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in Southeastern Sweden. Mov Disord 1999;14:28-37.
5. Jiménez-Jiménez FJ, Mateo D, Giménez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case control study. Mov Disord 1992;7:339-344.
6. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000;55:1350-1358.
7. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.
8. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
9. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 1999;39:936-940.
10. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-428.
11. Tsang KL, Jiang H, Ramsden DB, Ho SL. The use of estrogen in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2001;8: 133-137.
12. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 1998; 844:153-165.
13. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in Northern Manhattan, 1988-1993. Am J Epidemiol 1995;142:820-827.
14. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976- 1990. Neurology 1999;52:1214-1220.
15. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA working group. Italian longitudinal study on aging. Neurology 2000;55:1358-1363.
16. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Aschero A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001;50:780-786.
17. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
18. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50: 1141-1143.
19. Harrison M, Currie L, Trugman J, Bennett J, Wooten G. Effects of endogenous and exogenous estrogen on risk of Parkinson's disease. Neurology 2000;54:A444-A445.
20. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study. 20-year contribution to the understanding of health among women. J Womens Health 1997;6:49-62.
21. Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983;117:651-658.
22. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987;126:319-325.
23. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
24. Willett WC, Stampfer MJ, Manson JE, et al. Coffee consumption and coronary heart disease in women. A ten-year follow-up. JAMA 1996; 275:458-462.
25. Salvini S, Hunter D, Sampson L, Stampfer M, Colditz G, Willett W. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989;18:858-867.
26. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
27. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the national death index. Am J Epidemiol 1984;119:837-839.
28. Hu FB, Stampfer MJ, Rimm E, et al. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol 1999;149:531-540.
29. Rajput AH, Rozdilsky B, Rayput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991;18:275-278.
30. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
31. Rothman K, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998.
32. Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000;18:347-358.
33. Garcia-Segura LM, Azcoitia I, Don Carlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001;63:29-60.
34. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res 1998;54:707-719.
35. Sawada H, Ibi M, Kihara T, et al. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neuron. Faseb J 2000;14:1202-1214.
36. Sawada H, Shinohama S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci Biobehav Rev 2000;24:143-147.
37. Disshon KA, Dluzen DE. Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats. Brain Res 2000;868:95-104.
38. Callier S, Morissette M, Grandbois M, Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000;37:245-251.
39. Grandbois M, Morissette M, Callier S, Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuro-Report 2000;11:343-346.
40. Leranth C, Roth RH, Elswoth JD, Naftolin F, Horvath TL, Redmond DE. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000;20:8604-8609.
41. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov Disord 1986;1:85-87.
42. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol 1999;22:93-97.
43. Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. Int J Neurosci 1989;45:119-122.
44. Bedard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977;2:1367-1368.
45. Giladi N, Honingman S. Hormones and Parkinson's disease. Neurology 1995;45:1028-1029.
46. Thulin PC, Carter JH, Nichols MD. Menstrual-cycle related changes in Parkinson's disease. Neurology 1996;46:A376.
47. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999;52:1417-1421.
48. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292-2298.
49. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999;53:91-95.
50. Arnaud MJ. Metabolism of caffeine and other components of coffee. In: Garattini S, ed. Caffeine, coffee, and health. New York: Raven Press, 1993;43-95.
51. 2A antagonists in Parkinson's disease. Neurology 2002;58:1154-1160.
52. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by metabolites of caffeine may prolong its neuroprotective effect in the MPTP model of PD. Presented at the annual meeting of the Society for Neuroscience, Orlando, FL 2002.
53. Brown CR, Jacob P 3rd, Wilson M, Benowitz NL. Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clin Pharmacol Ther 1988;43:488-491.
54. George J, Murophy T, Roberts R, Cooksley WG, Halliday JW, Powell LW. Influence of alcohol and caffeine consumption on caffeine elimination. Clin Exp Pharmacol Physiol 1986;13:731-736.
55. Paulson G, Dadmehr N. Is there a premorbid personality typical for Parkinson's disease? Neurology 1991;41:73-76.